Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

View the 50 largest pharmaceutical companies in the world listings here

Amgen

Amgen

Rank: 15

Thousand Oaks, Calif., USA
www.amgen.com

2020 Revenues ($USD) : $24,240,000,000
2020 R&D spend : $4,207,000,000
2020 Number of Employees : 24,000
Fiscal Year End : 12/31/2020
Key People : Robert A. Bradway, chair, president and CEO; Esteban Santos, executive vice president of operations; Peter H. Griffith, CFO; David M. Reese, executive vice president of R&D; Darryl Sleep, chief medical officer and senior vice president of global medical; Mike Zahigian, chief information officer and senior vice president; Linda H. Louie, vice president of finance and chief accounting officer; Nancy A. Grygiel, chief compliance officer; David A. Piacquad, senior vice president of business development; Elliott M. Levy, SVP, strategy, operations, Research & Development; Murdo J. Gordon, executive vice president, Global Commercial Operations; Susan Sweeney, senior vice president, global marketing, access and capabilities; Arvind K. Sood, vice president of investor relations; Lori A. Johnston, senior vice president of human resources; Jonathan P. Graham, secretary, executive VP and general counsel; Victoria H. Blatter, senior vice president of U.S. government affairs

Amgen develops medications for cardiovascular disease, oncology, bone health, neurosciences, nephrology and inflammation therapies. It has 23 commercialized drugs on the market in the U.S. Enbrel, Amgen's tumor necrosis factor blocker, has led product sales at the company since 2018. The Thousand Oaks, Calif.–based company earlier this year announced plans to acquire Rodeo Therapeutics for $721 million and Five Prime Therapeutics for $1.9 billion in cash. –DK

Amgen

The Epogen bulk manufacturing plant in Thousand Oaks, Calif.

Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE